Wpływ chorób autoimmunologicznych tarczycy na rozwój otyłości brzusznej i hiperlipidemii by Tamer, Gonca et al.
421
PRACE ORYGINALNE/ORIGINAL PAPERS
Endokrynologia Polska/Polish Journal of Endocrinology
Tom/Volume 62; Numer/Number 5/2011
ISSN 0423–104X
 Effects of thyroid autoimmunity on abdominal obesity 
and hyperlipidaemia
Wpływ chorób autoimmunologicznych tarczycy na rozwój otyłości brzusznej 
i hiperlipidemii
Gonca Tamer1, Meral Mert2, Ismet Tamer3, Banu Mesci4, Damla Kılıc4, Safiye Arık4
1Division of Endocrinology and Metabolism, Department of Internal Medicine, Göztepe Training and Research Hospital, 
Istanbul, Turkey
2Division of Endocrinology and Metabolism, Department of Internal Medicine, Okmeydani Training and Research Hospital, 
Istanbul, Turkey
3Department of Family Medicine, Kartal Training and Research Hospital, Istanbul, Turkey
4Department of Internal Medicine, Göztepe Training and Research Hospital, Istanbul, Turkey
Abstract
Background: Thyroid autoimmunity has been suggested as a risk factor for atherosclerosis independent of thyroid function in several 
studies. The aim of this study was to investigate whether thyroid autoimmunity had any effect on hyperlipidaemia, obesity and abdominal 
obesity independent of thyroid function. 
Material and methods: 184 premenopausal female patients with Hashimoto’s thyroiditis (HT) and 150 healthy premenopausal female 
volunteers as control group (CG) were included in the study. According to thyroid function status, the patients were divided into three 
subgroups: overt hypothyroid patients (ohp), subclinical hypothyroid patients (shp) and euthyroid patients (ep). Body mass index (BMI), 
waist to hip ratios, waist circumference (WC), and serum lipid levels of all the participants were determined. These parameters of ep were 
compared with those of ohp, shp and CG. Relationships among thyroid stimulating hormone (TSH), thyroid autoantibodies and lipid 
levels were investigated. 
Results: There were no significant differences between serum total cholesterol and low density lipoprotein cholesterol (LDL-C) levels of ohp 
and ep with HT (P = 0.18, P = 0.07 respectively) and LDL-C levels of ep were higher than those of CG (P = 0.03, P = 0.042, respectively). 
Although TSH levels did not correlate with serum lipid levels, levels of anti-thyroid peroxidase antibody correlated with triglyceride levels 
and WCs (r = 0.158; P = 0.013, r = 0.128; P = 0.048 respectively) and negatively correlated with high density lipoprotein cholesterol (HDL-C) 
levels (r = –0.137; P = 0.031). Levels of anti-thyroglobulin antibody also correlated with triglyceride and nonHDL-C levels (r = 0.208; 
P = 0.007, r = 0.158; P = 0.043 respectively). 
Conclusion: Thyroid autoimmunity may have some effects on hyperlipidaemia and abdominal obesity independent of thyroid function.
(Pol J Endocrinol 2011; 62 (5): 421–428)
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Streszczenie
Wstęp: Wyniki badań wskazują, że choroby autoimmunologiczne tarczycy są czynnikiem ryzyka miażdżycy, bez względu na czynność 
tego narządu. Celem badania było ustalenie, czy obecność chorób autoimmunologicznch tarczycy niezależnie od jej funkcji wpływa na 
rozwój hiperlipidemii, otyłości i otyłości brzusznej.
Materiał i metody: Do badania włączono 184 kobiet przed menopauzą z zapaleniem tarczycy typu Hashimoto (HT) i 150 zdrowych 
ochotniczek przed menopauzą, które stanowiły grupę kontrolną (CG). Chore podzielono na 3 podgrupy w zależności od stanu czynno-
ściowego tarczycy: osoby z jawną niedoczynnością tarczycy (ohp), z bezobjawową niewydolnością tarczycy (shp) i osoby z eutyreozą (ep). 
U wszystkich uczestniczek badania określono wskaźnik masy ciała (BMI), wskaźnik talia/biodra, obwód talii i stężenia lipidów w surowicy. 
Powyższe parametry porównano między grupą ep i pozostałymi grupami (ohp, shp, CG). Zbadano zależności  między stężeniem TSH, 
przeciwciał przeciwtarczycowych i stężeniami lipidów.
Wyniki: Nie stwierdzono istotnych różnic między stężeniami cholesterolu całkowitego i cholesterolu frakcji LDL między grupami ohp 
i ep (odpowiednio p = 0,18 i p = 0,07). Stężenia cholesterolu frakcji LDL w grupie ep były wyższe niż w grupie CG (odpowiednio p = 0,03 
i p = 0,042). Stężenia TSH nie korelowały ze stężeniami lipidów w surowicy, jednak stwierdzono prostą zależność między stężeniami 
przeciwciał przeciw peroksydazie tarczycowej i stężeniami triglicerydów oraz obwodem talii (odpowiednio r = 0,158; p = 0,013, r = 0,128; 
p = 0,048) i odwrotną zależność między cholesterolem frakcji HDL (r = –0,137; p = 0,031). Stężenia przeciwciał przeciw tyreoglobulinie 
korelowały ze stężeniami triglicerydów i cholesterolu nie-HDL (odpowiednio r = 0,208; p = 0,007, r = 0,158; p = 0,043).
Wnioski: Choroby autoimmunologiczne tarczycy mogą wpływać na rozwój hiperlipidemii i otyłości brzusznej niezależnie od stanu 
czynnościowego tego narządu. (Endokrynol Pol 2011; 62 (5): 421–428)
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Introduction
Hypothyroidism is a known common risk factor for 
obesity and hyperlipidaemia. Hashimoto’s thyroiditis 
(HT) is the commonest cause of hypothyroidism [1–4]. 
But it is not clear if thyroid autoimmunity is a risk fac-
tor for obesity and hyperlipidaemia independent of 
thyroid function.
The involvement of thyroid autoimmunity in at-
herosclerosis as a risk factor for coronary heart disease 
independent of thyroid function has been suggested in 
some previous studies. Increased serum levels of circu-
lating thyroid and/or other autoantibodies have often 
been observed in the atherosclerotic process [5–10]. 
In 1991, Volpe suggested that HT is predominantly 
a disorder of cell-mediated immunity that is manifested 
by a genetic defect in the suppressor T-cell function [11]. 
According to this hypothesis, in HT, helper (CD4) T cells 
are not suppressed because of the defective suppressor 
T cells, and therefore are able to produce various cyto-
kines such as interferon (IFN)-g, interleukin (IL)-2 and 
tumour necrosis factor (TNF)-a [12].
Recently, a study performed in mice determined that 
(IFN)-g regulates fat inflammation and TNF-a promotes 
lipogenesis and induces lipolysis [13].
There are a few studies suggesting that thyroid auto-
immunity is a risk factor for atherosclerosis independent 
of thyroid function. However in HT, T helper cells may 
not be suppressed and can produce some cytokines 
such as IFN-g and TNF-a as suggested by Volpe [11]. 
These cytokines might cause weight gain, lipogenesis 
and lipolysis in humans as in mice, as suggested by 
Sultan [13].
Combining Volpe’s hypothesis with Sultan’s find-
ing, it is possible that thyroid autoimmunity might 
cause weight gain and hyperlipidaemia independent 
of thyroid function.
 In this study, we hypothesised that thyroid auto-
immunity may have some effects on hyperlipidaemia, 
obesity and abdominal obesity independent of thyroid 
function. 
With this aim, we investigated body mass index 
(BMI), waist circumference (WC), waist to hip ratio 
(WHR), rates of obesity and abdominal obesity and total 
cholesterol (TC), high density lipoprotein cholesterol 
(HDL-C), triglyceride (TG), low density lipoprotein 
cholesterol (LDL-C), and non-high density lipoprotein 
cholesterol (non-HDL-C) levels of euthyroid patients 
(ep) with Hashimoto’s thyroiditis, and compared them 
with those of overt hypothyroid patients (ohp), subclini-
cal hypothyroid patients (shp) and healthy subjects. We 
also examined if each one of those lipid parameters, 
BMIs, WCs and WHRs correlated with serum thyroid 
stimulating hormone (TSH), autoantibodies against 
thyroglobulin (TgAb) and thyroid peroxidase (TPOAb) 
concentrations separately in all the patients with HT.
Material and methods
The study included 184 premenopausal female pa-
tients with newly diagnosed and untreated HT and 
150 healthy premenopausal female volunteers as the 
control group (CG). All CG subjects were matched for 
age with HT patients (Table I). This study was approved 
by our institutional ethics committee (approval date and 
number: 21.02.2008, 44/E) and the study subjects have 
therefore been recruited to the study in accordance with 
ethical standards announced in the 1964 Declaration of 
Helsinki. All the subjects in this study gave informed 
consent prior to their inclusion. 
Lymphocytic infiltration of the thyroid gland is 
present up to 40% of healthy women [3, 14] and it is 
known that loss of oestrogen at the menopause causes 
an increase in serum LDL-C levels and weight gain [15]. 
Therefore, the present study was designed to include 
premenopausal women. Patients with liver disorders, 
renal disorders, congestive heart failure, diabetes mel-
litus, pregnant women, patients on oral contraceptive 
pills, fibrates and/or statins, steroids, thiazides, beta 
blockers, or with other medications that might alter or 
influence body weight, serum lipid levels or thyroid 
functions were excluded from the study. A diagnosis 
of HT was made in the presence of elevated antithy-
roid peroxidase and antithyroglobulin antibodies and 
ultrasound patterns suggestive of HT [2].
HT patients were classfied into three subgroups 
according to their thyroid function status. Overt hy-
pothyroid patients (ohp, n = 51; 27.71%) were those 
with serum TSH > 10 uIU/mL (reference interval was 
0.27–4.2 uIU/mL) and free T4 < 0.93 ng/dL (reference 
interval was 0.93–1.7 ng/dL). 
Subclinical hypothyroid patients (shp, n = 49; 
26.63%) were those with normal serum free T4 and free 
T3 levels but with high serum TSH levels. 
Euthyroid patients (ep, n = 84; 54.34%) were those 
with HT but normal free T4 and TSH levels [3, 14]. 
BMI was calculated as body weight (kg) divided by 
height (m) squared [16] and obesity was defined as BMI 
of 30 or more (kg/m2) [17, 18]. Waist and hip circumfe-
rences of all the patients were measured and waist to 
hip ratios (WHRs) were calculated.
Waist circumferences were measured at the plane 
between anterior superior iliac spines and lower costal 
margins at the narrowest part of the waistline while 
patients were standing during slight expiration [16–18]. 
For women, WC > 88 cm was accepted as abdominal 
obesity according to WC [19]. Hip circumferences 
were measured horizontally over the furthest points 
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of trochanters while standing with 20–30 cm distance 
between feet. A measure of WHR > 0.85 was accepted 
as abdominal obesity for women [17, 19].
Blood samples were taken following 12 hours of 
fasting, and immediately centrifuged (2,500 rpm) and 
the sera were separated. TC, HDL-C and TG levels 
were determined by enzymatic methods and LDL-C 
levels were determined using the Friedewald formula 
[20]. Those patients whose TG levels were higher than 
400 mg/dL were excluded from the study as they might 
have limitation of the calculation of LDL-C levels [20]. 
Serum autoantibodies against thyroglobulin (TgAb) 
and thyroid peroxidase (TPOAb), TSH, free T3 and free 
T4 levels were measured by electrochemiluminescence 
immunoassay ECLIA (Modular Analytics E170; Roche 
Diagnostics). The normal ranges were 0–34 IU/mL for 
TPOAb levels and 0–115 IU/mL for TgAb levels.
Statistical analysis
All statistical analyses were made using SPSS 13.0. 
Normality of the distribution of variables was tested 
by Shapiro-Wilk and Kolmogorov-Smirnov tests. Waist 
circumference, total cholesterol, non-HDL cholesterol, 
HDL-C and LDL-C were compared by independent 
samples t — test in all hypothyroidism patients and 
control group, in ohp and control group, in shp and 
control group, and in ep and control group. The same 
parameters were compared by one-way analysis of va-
riance (ANOVA) for more than two categories. TG, BMI, 
WHR, TSH, TPOAb and TgAb were compared by the 
Wilcoxon–Mann–Whitney U test in all hypothyroidism 
patients and control group, in ohp and control group, 
in shp and control group, and in ep and control group. 
The same parameters were compared by Kruskal Wallis 
test for groups with more than two levels. A factorial 
logistic regression was used when we had two or more 
categorical independent variables but a dichotomous 
dependent variable. Pearson’s correlation coefficients 
among TSH, TPOAb, Tg Ab, BMI, WC, WHR, lipid para-
meters were determined using regression analyses. Data 
was reported as means ± SD. Significant differences 
were assumed for p < 0.05.
Results
Characteristics of all subjects are shown in Tables I–IV. 
Serum TC, LDL-C, TG and non-HDL-C levels of all 
the patients with HT were significantly higher than 
those of CG (P = 0.01, P = 0.002, P = 0.001, P < 0.0001, 
respectively) (Table I). Means of BMI and WC, rates of 
obesity and abdominal obesity according to WC, serum 
TC, LDL-C, TG and non-HDL-C levels of ohp were sig-
nificantly higher than those of CG (P = 0.026, P = 0.01, 
P = 0.013, P = 0.029, P = 0.01, P = 0.001, P = 0.001, 
P = 0.001, respectively) (Table II). We interestingly 
Table I. Comparison of the characteristics of patients with Hashimoto’s thyroiditis  [HT] and the control group
Tabela I. Porównanie parametrów między chorymi na zapalenie tarczycy typu Hashimoto (HT) i kobietami z grupy kontrolnej
Patients with HT 
(n = 184)
Control group 
(n = 150)
p
Age 35.48 ± 7.92 35.71 ± 7.85 NS
TSH [uIU/mL] 15.51 ± 44.88 1.69 ± 0.93 0.0005
TPOAb [IU/mL] 292.47 ± 361.7 11.7 ± 33.6 0.0005
TgAb [IU/mL] 461.22 ± 788.46 21.95 ± 43.38 0.0005
BMI 28.30 ± 6.21    27.98 ± 7.09 NS
Rate of obesity 60  [34.3%] 44 [29.7%] NS
WC [cm] 88.89 ± 3.14    86.27 ± 14.80 NS
Rate of abdominal obesity according to WC 88 [53.3%] 66 [47.1%] NS
WHR [cm] 0.809 ± 0.06 0.801 ± 0.7 NS
Rate of abdominal obesity according to WHR 47 [28.7%] 40  [28.6%] NS
TC [mg/dL] 197.12 ± 38.96 184.79 ± 36.23 0.01
LDL-C [mg/dL] 129.55 ± 30.63 116.39 ± 28.57 0.002
HDL-C [mg/dL] 54.84 ± 13.09 56.19 ± 14.88 NS
TG [mg/dL] 118.20 ± 66.85 97.92 ± 58.95 0.001
non-HDL-C [mg/dL] 142.28 ± 36.40 128.60 ± 3413 < 0.0001
BMI — body mass index; WC — waist circumference; WHR — waist-to-hip ratio; TC — total cholesterol; LDL-C — low-density lipoprotein cholesterol; 
HDL-C — high-density lipoprotein cholesterol; TG — triglyceride; non-HDL-C — non-high-density lipoprotein cholesterol; NS — non-significant
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Table II. Comparison of the characteristics of overt hypothyroid patients  [ohp] with Hashimoto’s thyroiditis (HT) 
and control group
Tabela II. Porównanie parametrów między grupą chorych na zapalenie tarczycy typu Hashimoto (HT) z jawną niedoczynnością 
tarczycy (ohp) i grupą kontrolną
ohp with HT 
(n = 51)
Control Group 
(n = 150)
p
Age 35.75 ± 7.75 35.71 ± 7.85 NS
TSH [uIU/mL] 31.83 ± 31.47 1.69 ± 0.93 0.0005
TPOAb [IU/mL] 421.19 ± 551.99 11.70 ± 33.6 0.0005
TgAb [IU/mL] 574.48 ± 1016.6 21.95 ± 43.38 0.0005
BMI 30.34 ± 6.69 27.98 ± 7.09 0.026
Rate of obesity 26  [52%] 44 [29.7%] 0.013
WC [cm] 93.17 ± 13.35 86.27 ± 14.80 0.010
Rate of abdominal obesity according to WC 28 [68.3%] 66 [47.1%] 0.029
WHR [cm] 0.816 ± 0.72 0.801 ± 0.7 NS
Rate of abdominal obesity according to WHR 10 [24.4%] 40  [28.6%] NS
TC [mg/dL] 202.53 ± 41.41 184.79 ± 36.23 0.01
LDL-C [mg/dL] 136.14 ± 33.55 116.39 ± 28.57 0.001
HDL-C [mg/dL] 51.52 ± 11.86 56.19 ± 14.88 NS
TG [mg/dL] 131.25 ± 73.66 97.92 ± 58.95 0.001
non-HDL-C [mg/dL] 151.31 ± 39.24 128.60 ± 3413 0.001
Table III. Comparison of the characteristics of subclinical hypothyroid patients  [shp] with Hashimoto’s thyroiditis (HT) 
and control group
Tabela III. Porównanie parametrów między grupą chorych na zapalenie tarczycy typu Hashimoto (HT) z bezobjawową 
niedoczynnością tarczycy (shp) i grupą kontrolną
shp with HT 
(n = 49)
Control group 
(n = 150)
p
Age 35.94 ± 8.75 35.71 ± 7.85 NS
TSH [uIU/mL] 21.04 ± 77.66 1.69 ± 0.93 0.0005
TPOAb [IU/mL] 296.45 ± 312.92 11.7 ± 33.6 0.0005
TgAb [IU/mL] 603.36 ± 974.77 21.95 ± 43.38 0.0005
BMI 26.81 ± 5.81 27.98 ± 7.09 NS
Rate of obesity 12  [26.1%] 44 [29.7%] NS
WC [cm] 86.27 ± 14.59 86.27 ± 14.80 NS
Rate of abdominal obesity according to WC 21 [47.7%] 66 [47.1%] NS
WHR [cm] 0.802 ± 0.64 0.801 ± 0.7 NS
Rate of abdominal obesity according to WHR 10 [23.3%] 40  [28.6%] NS
TC [mg/dL] 196.39 ± 41.03 184.79 ± 36.23 NS
LDL-C [mg/dL] 128.24 ± 33.02 116.39 ± 28.57 0.031
HDL-C [mg/dL] 54.02 ± 13.37 56.19 ± 14.88 NS
TG [mg/dL] 112.11 ± 62.72 97.92 ± 58.95 NS
non-HDL-C [mg/dL] 142.37 ± 40.07 128.60 ± 3413 NS
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Table V. Comparison of the characteristics of overt hypothyroid patients  [ohp], subclinical hypothyroid patients (shp) 
and euthyroid patients (ep)
Tabela V. Porównanie parametrów między grupami chorych na zapalenie tarczycy typu Hashimoto (HT) z jawną niewydolnością 
tarczycy (ohp), bezobjawową niewydolnością tarczycy (shp) i eutyreozą (ep)
ohp (n = 51) shp (n = 49) ep (n = 84) p
Age 35.75 ± 7.75 35.94 ± 8.75 35.5 ± 7.58 NS
TSH [uIU/mL] 31.83 ± 31.47 21.044 ± 77.66 2.38 ± 1.05 0.0005
TPOAb [IU/mL] 421.19 ± 551.99 296.45 ± 312.92 212.77 ± 176.78 0.001
TgAb [IU/mL] 574.48 ± 1016.61 603.36 ± 974.77 305.14 ± 378.74 NS
BMI 30.34 ± 6.69 26.81 ± 5.81 27.88 ± 7.09 0.03
Rate of obesity 26 (52%) 12 (26.1%) 22 (27.8%) NS
WC [cm] 93.17 ± 13.35 86.27 ± 14.59 88.13 ± 11.77 0.04
Rate of abdominal obesity according to WC 28 (68.3%) 21 (47.7%) 39 (48.8%) NS
WHR [cm] 0.816 ± 0.72 0.802 ± 0.64 0.81 ± 0.58 NS
Rate of abdominal obesity according to WHR 10 (24.4%) 10 (23.3%) 27 (33.8%) NS
TC [mg/dL] 202.53 ± 41.41 196.39 ± 41.03 194.17 ± 36.26 NS
LDL-C [mg/dL] 136.14 ± 33.55 128.24 ± 33.02 126.27 ± 26.92 0.01
HDL-C [mg/dL] 51.52 ± 11.86 54.02 ± 13.37 57.56 ± 13.2 NS
TG [mg/dL] 131.25 ± 73.66 112.11 ± 62.72 113.5 ± 64.31 0.01
non-HDL-C [mg/dL] 151.31 ± 39.24 142.37 ± 40.07 136.61 ± 31.39 NS
Table IV. Comparison of the characteristics of euthyroid patients (ep) with Hashimoto’s thyroiditis (HT) and control group
Tabela IV. Porównanie parametrów między grupą chorych na zapalenie tarczycy typu Hashimoto (HT) z eutyreozą (ep) 
i grupą kontrolną
ep with HT 
(n = 84)
Control group 
(n = 150)
p
Age 35.05 ± 7.58 35.71 ± 7.85 NS
TSH [uIU/mL] 2.38 ± 1.05 1.69 ± 0.93 0.0005
TPOAb [IU/mL] 212.77 ± 176.78 11.70 ± 33.60 0.0005
TgAb [IU/mL] 305.14 ± 378.74 21.95 ± 43.38 0.0005
BMI 27.88 ± 7.09 27.98 ± 7.09 NS
Rate of obesity 22  [27.8%] 44 [29.7%] NS
WC [cm] 88.13 ± 11.77 86.27 ± 14.80 NS
Rate of abdominal obesity according to WC 39 [48.8%] 66 [47.1%] NS
WHR [cm] 0.81 ± 0.58 0.801 ± 0.7 NS
Rate of abdominal obesity according to WHR 27 [33.8%] 40  [28.6%] NS
TC [mg/dL] 194.17 ± 36.26 184.79 ± 36.23 NS
LDL-C [mg/dL] 126.27 ± 26.92 116.39 ± 28.57 0.0042
HDL-C [mg/dL] 57.56 ± 13.2 56.19 ± 14.88 NS
TG [mg/dL] 113.5 ± 64.31 97.92 ± 58.95 NS
non-HDL-C [mg/dL] 136.61 ± 31.39 128.60 ± 3413 NS
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determined that LDL-C levels of ep were significantly 
higher than those of CG (P = 0.042) (Table IV). LDL 
levels of shp were also significantly higher than those 
of CG (P = 0.031) (Table III). Contrary to expectations, 
TSH levels did not correlate with LDL-C levels in all 
the patients with HT (r = 0.045; P = 0.551). Total cho-
lesterol, TG, nonHDL-C, and HDL-C levels did not 
correlate with TSH levels either (r = 0.039; P = 0.606, 
r = 0.063; P = 0.399, r = 0.044; P = 0.554, r = –0.008; 
P = 0.914 respectively). We surprisingly observed that 
serum TPOAb concentrations correlated with TG levels 
and WCs (r = 0.158; P = 0.013, r = 0.128; P = 0.048 res-
pectively) and negatively correlated with HDL-C levels 
in all the patients with HT (r = –0.137; P = 0.031). Se-
rum TgAb concentrations also correlated with TG and 
nonHDL-C levels in all the patients with HT (r = 0.208; 
P = 0.007, r = 0.158; P = 0.043 respectively). TSH levels 
correlated with TgAb levels (r = 0.187; P = 0.015), but 
did not correlate with TPOAb levels in all the patients 
with HT (r = 0.081; P = 0.280).
Serum TSH and TPOAb levels of ohp were signifi-
cantly higher than those of ep (P = 0.0005, P = 0.0005, 
respectively), and those of shp (P = 0.0005, P = 0.044, 
respectively). However, there was no significant diffe-
rence among TgAb levels of ohp, shp and ep (P = 0.19). 
Body mass index, WC and rate of obesity of ohp 
were higher than those of shp (P = 0.006, P = 0.023, 
P = 0.009, respectively). Between ohp and shp, there 
was no significant difference concerning serum TC, 
LDL-C, HDL-C, TG and non-HDL-C levels, and rates 
of abdominal obesity according to WC and WHR. 
(P = 0.40, P = 0.27, P = 0.37, P = 0.11, and P = 0.25, 
P = 0.054, P = 0.903, respectively). Body mass index 
and WC and rates of obesity and abdominal obesity 
according to WC of ohp were significantly higher 
than ep (P = 0.037, P = 0.035, P = 0.006, P = 0.039, 
respectively). Serum TG and non-HDL levels of ohp 
were also higher than those of ep (P = 0.04, P = 0.02, 
respectively) and serum HDL-C levels of ep with HT 
were higher than those of ohp (P = 0.02). But there 
was no significant difference between serum TC 
and LDL-C levels of ohp and ep with HT (P = 0.18, 
P = 0.07 respectively).
Discussion
Unlike most previous studies, in the present study 
serum LDL-C levels of ep with HT were determined 
to be higher than those of healthy subjects and there 
was no significant difference between serum TC and 
LDL-C levels of ohp and of ep with HT. Not only ohp 
but also all the patients with HT had higher serum 
TC, LDL-C, TG, and non HDL-C levels compared to 
healthy subjects. There were no correlations between 
TSH and LDL-C levels or between TSH and other lipid 
parameters in all the patients with HT. However, TPOAb 
concentrations negatively correlated with HDL-C and 
positively correlated with TG levels and WCs in all the 
patients with HT. Serum TgAb concentrations also cor-
related with TG and nonHDL-C levels. 
These findings suggest that thyroid autoimmunity 
may be associated with hyperlipidaemia independent 
of thyroid function, as suggested in the old studies by 
the Bastenie et al. [8–10]. Overt hypothyroidism (OH) 
is not only one of the causes of obesity but also a risk 
factor for atherosclerotic cardiovascular disease and 
hyperlipidaemia as well. Moreover, OH has been found 
to be associated with insulin resistance [21]. 
It is known that serum TC, LDL-C, TG, free fatty 
acid (FFA) levels and BMIs of ohp are higher than those 
of healthy subjects [3, 21–25]. Elevated levels of FFAs 
stimulate insulin secretion, placing a further burden on 
genetically compromised and stressed -cell function in 
individuals susceptible to type 2 diabetes. Furthermore, 
elevated FFAs have been reported to impair early insulin 
secretion, a characteristic B-cell abnormality in type 2 
diabetes. In addition, increased flux of FFA to the liver 
increases hepatic gluconeogenesis and hepatic glucose 
output, adding to already existing abnormalities in 
hepatic glucose metabolism in type 2 diabetes [1]. Re-
cently, it has been demonstrated that insulin resistance 
may modify the relationship between lipids and thyroid 
function and the association between elevated TSH and 
LDL-C levels varies depending on the degree of insulin 
sensitivity [26–31].
In the present study, BMI, WC, rates of obesity and 
abdominal obesity according to WC, serum TC, TG, 
LDL-C and non-HDL-C levels of ohp with HT were 
higher than those of healthy subjects, but there was no 
significant difference between HDL-C levels of ohp and 
those of healthy people. 
Many studies have investigated the relationship 
between thyroid function and serum lipid levels and 
determined various findings. A large cross-sectional 
survey of 3,410 elderly subjects in Maryland noted 
significantly elevated LDL-C levels in subjects with 
subclinical hypothyroidism, but no increased frequency 
of diagnosed atherosclerotic disease could be found in 
the entire cohort of shp [32]. McDermott et al. found 
that overt hypothyroidism and also subclinical hypo-
thyroidism (SH) lead to increased blood pressure and 
triglyceride levels and decreased HDL-C levels [33]. Ca-
naris determined that shp had higher serum cholesterol 
levels than ep [34], and in another study it was observed 
that LDL-C levels were higher and HDL-C levels were 
lower in shp than those in healthy subjects [35].
A report from Rotterdam noted that shp actually 
had lower TC levels than controls, but manifested inc-
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reased atherosclerotic cardiovascular disease [36], This 
finding suggests that some other factors contribute to 
the increased risk of atherosclerosis independent of se-
rum TC levels [36]. In another large study, no difference 
could be determined between serum cholesterol levels 
of shp and those of healty subjects [37]. Uzunlulu et 
al. did not observe any difference between serum TG, 
HDL-C levels of 36 shp and of 190 healthy subjects [38]. 
Shantha et al. also could not determine any difference 
among serum TC, TG, HDL-C levels of 92 shp, 31 ohp 
and 406 healthy subjects [39].
In the present study, serum LDL-C levels of shp 
and ep were higher than healthy subjects. However, 
there was no significant difference between serum TC, 
TG, HDL-C and non-HDL-C levels of shp with HT and 
healthy people, and also between those of ep with HT 
and healthy subjects.
Contrary to the studies which determined the asso-
ciation between high TSH levels and hyperlipidaemia, 
another study has identified subclinical hypothyroidism 
as an independent risk factor for aortic atherosclerosis 
and myocardial infarction in elderly women [36].
In the present study, it was determined that TSH 
levels suprisingly did not correlate with LDL-C levels 
or other lipid parameters.
Based on the data, the association between overt 
hypothyroidism and cardiovascular disease or between 
subclinical hypothyroidism and cardiovascular disease 
may not be entirely explained by dyslipidaemia alone. 
The involvement of the immune system in atheroscle-
rosis is mainly suggested by the presence of activated 
T cells within the atherosclerotic lesions and of circula-
ting autoantibodies to plaque components. Two studies 
focused on the involvement of two major autoantigenic 
determinants in the atherogenic process, namely, the 
heat shock protein and oxi LDL-C [5, 6]. According to 
this view, after early activation of the immune system, 
the progression of the atherosclerotic lesions would be 
enhanced by focal secretion of cytokine and growth 
factor networks. In the framework of the above scena-
rio, the increased serum levels of circulating thyroid 
and/or other autoantibodies are often observed in the 
elderly and reflect an ongoing autoimmune activation 
involved in the atherosclerotic process leading to inc-
reased risk of coronary heart disease. No direct support 
to this hypothesis has been provided. However, in 
one of the few studies addressing this question more 
directly, a significant correlation was found in humans 
between atherosclerotic lesions and circulating anti-hsp 
65 antibodies, while in the same patients, the arterial 
damage was unrelated to serum thyroid and other 
autoantibodies [5, 7]. 
On the epidemiological basis, thyroid autoimmu-
nity as a risk factor for coronary heart disease inde-
pendent of thyroid function, as suggested by Bastenie 
et al. [8–10], has not been confirmed in more recent 
investigations [40]. 
Many studies determined that elevated serum li-
pid levels were associated with TSH elevations. In the 
HUNT study, the association of hypothyroidism with 
high serum lipids was linear across the entire reference 
range of TSH [41]. Tagami et al. determined positive 
correlation between serum TSH and lipid levels [42]. 
However, the Whickham study showed that elevated 
serum lipid levels were not associated with TSH eleva-
tions [43] and during the follow up of the Whickham 
survey, investigators found no association between 
elevated serum TSH and the increased risk of ischaemic 
heart disease or dyslipidaemia [44]. 
Complying with the Whickam study, in the pre-
sent study, TSH levels did not correlate with serum 
lipid levels, BMI and WC. However, it was suprisingly 
found that TPOAb concentrations correlated with TG 
levels and WC and negatively correlated with HDL-C 
levels and TgAb concentrations correlated with TG and 
nonHDL-C levels. Besides, serum LDL-C levels of ep 
with HT were found to be higher than those of healthy 
subjects and there was no significant difference between 
serum TC and LDL-C levels of ohp and ep with HT. It 
was another notable finding in the study that there was 
no significant difference between TgAb levels of ohp 
and those of ep. 
These findings support the idea that thyroid autoim-
munity is a risk factor for hyperlipidaemia independent 
of the thyroid function.
It is not clear how thyroid autoimmunity affects obe-
sity, abdominal obesity and serum lipid levels. However, 
in HT it is possible that increased IFN-g and TNF-a may 
cause obesity and hyperlipidaemia without elevated 
TSH levels.
In conclusion, although overt hypothyroidism has 
more effect on hyperlipidaemia and obesity, thyroid 
autoimmunity may have some effects on hyperlipida-
emia and abdominal obesity independent of thyroid 
function. Therefore it may be beneficial to determine 
the TC, LDL-C, HDL-C, TG, nonHDL-C levels and WCs 
of all patients with HT, even if they are euthyroid. Furt-
her studies are needed to investigate the relationships 
between thyroid autoantibodies and hyperlipidaemia 
and between thyroid autoantibodies and abdominal 
obesity.
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